4 / 6

2025年7月17日

Post-market activities including PMS and product liability – 4 / 6 观点

Medical devices: additional regulatory considerations from the new liability frameworks

In this article we examine why this burden is particularly difficult for multi-national life sciences businesses and explain the steps you should be taking now to mitigate against potential court sanctions for failure to disclose relevant evidence.

  • Briefing
更多
作者

Katie Chandler

合伙人

Read More

Alison Dennis

合伙人

Read More

Megan Howarth

高级律师

Read More

Return to

Synapse home

Go to Synapse main hub